{"nctId":"NCT02023164","briefTitle":"Pilot Phase III Clinical Trial of JDP-205 IV Injection for Treatment of Acute Urticaria","startDateStruct":{"date":"2013-07"},"conditions":["Acute Urticaria"],"count":36,"armGroups":[{"label":"Test Drug","type":"EXPERIMENTAL","interventionNames":["Drug: JDP-205 Injection"]},{"label":"Control","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Diphenhydramine"]}],"interventions":[{"name":"JDP-205 Injection","otherNames":["Cetirizine","Quzyttir"]},{"name":"Diphenhydramine","otherNames":["Benadryl","DPH"]}],"eligibilityModule":{"eligibilityCriteria":"Patients are eligible to be included in the study only if they meet all of the following criteria:\n\nInclusion Criteria:\n\n* Male or female patients with a diagnosis of acute urticaria associated with an acute allergic reaction to a known (e.g. food, medication, insect bites) or unknown allergen who need treatment with an injectable antihistamine to alleviate their symptoms;\n* 18 years of age or older;\n* Be willing and able to give informed consent;\n* Patients with a Physician Pruritus Severity Score ≥ 1 (determined by the investigator);\n* Patients with an Extent of Urticaria/Erythema Score ≥ 1 (determined by the investigator).\n\nExclusion Criteria:\n\n* Receipt of an investigational drug or device, within the past 30 days;\n* Patients in whom an antihistamine may be contraindicated (e.g. narrow angle glaucoma, symptomatic prostatic hypertrophy);\n* Patients who, in the opinion of the investigator, may not tolerate an IV injection of diphenhydramine 50 mg, or cetirizine 10 mg;\n* Receipt of any antihistamine (H1 antagonist) within the past 4 hours regardless of the route of administration, e.g. diphenhydramine, cetirizine, loratadine, fexofenadine, levocetirizine, desloratadine;\n* Receipt of an H2 antagonist within the past 12 hours;\n* Receipt of doxepin within the past 48 hours; doxepin is an antidepressant, but it also has antihistamine properties;\n* Receipt of steroids by the oral, IV, IM, or inhalational routes route within the past 48 hours to manage an acute allergic reaction;\n* Receipt of epinephrine (EpiPen or any other brand) within the past 1 hour;\n* Has known allergy to hydroxyzine, cetirizine or levocetirizine, or diphenhydramine;\n* Pregnancy or breastfeeding;\n* Patients who require epinephrine immediately to manage their acute allergic symptoms;\n* Patients who have an acute reaction to medication they are taking (e.g. antibiotics, ACE inhibitors, NSAIDs) and who cannot stop the medication;\n* Patients who, based on their medical history or in the opinion of the investigator, have chronic idiopathic urticaria, hereditary angioedema, urticaria refractory to antihistamines, or dermatological disease that interferes with evaluation of a therapeutic response;\n* Urticaria not associated with an acute allergic reaction;\n* Any condition that in the view of the investigator makes the subject unsuitable for enrollment in this study;\n* History of HIV or other known immunodeficiency;\n* Major medical or psychiatric illness, other than acute urticaria, at the time of presentation;\n* Inability to provide informed consent.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Extent of Urticaria/Erythema Score (Physician Assessment)","description":"Extent of Urticaria/Erythema Score (Physician Assessment), capturing extent of urticaria/erythema, using the Body Chart (adopted from Burn Chart).\n\nExtent of Urticaria/Erythema Score is the average of the 2 scores:\n\n1. Percentage of body area using the body chart (adopted from burn Chart) 0 = none, 1= mild (,25% body coverage), 2 = moderate (25-50% body coverage, 3 = Severe/intense .50% body coverage\n2. Intensity of redness (adopted from PASI) 0 = none, 1 = mile (light pink) 2= moderate (pink), 3 =severe/intense (red)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.91","spread":"0.61"},{"groupId":"OG001","value":"1.74","spread":"0.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.53","spread":"0.74"},{"groupId":"OG001","value":"1.12","spread":"1.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.89","spread":"0.60"},{"groupId":"OG001","value":"1.35","spread":"1.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.09","spread":"0.55"},{"groupId":"OG001","value":"0.97","spread":"0.94"}]}]}]},{"type":"PRIMARY","title":"Physician Pruritus Severity Score","description":"Physician Pruritus Severity Score based on patient expression of severity of itchiness.\n\n0= none\n\n1 = Mild (patient expresses itchiness but tolerable, and does not scratch 2= moderate definite awareness, bothersome, intermittently scratch affected area 3= severe difficult to tolerate scratch vigorously","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.","spread":null},{"groupId":"OG001","value":"2.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"1.","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Patient Pruritis Severity Score","description":"Patient Pruritis Severity Score based on severity of itching at time of assessment.\n\nHow severly are your hives itching at the moment? 0 = none\n\n1= mild minimal awareness easily tolerated 2 = moderate definite awareness quite bothersome 3= severe difficult to tolerate","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.19","spread":"0.66"},{"groupId":"OG001","value":"2.24","spread":"1.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.56","spread":"0.63"},{"groupId":"OG001","value":"0.82","spread":"1.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.56","spread":"0.53"},{"groupId":"OG001","value":"0.90","spread":"1.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.52"},{"groupId":"OG001","value":"0.59","spread":"1.06"}]}]}]},{"type":"PRIMARY","title":"Composite Acute Urticaria Score Change From Baseline","description":"A composite acute urticaria score, the sum of Extent of urticaria/erythema score (Physician), Physician pruritis score and Patient pruritis severity score. A composite acute urticaria score which the sum of the above three parameters (i.e. 0-9) was calculated post hoc for each patient at each time point and then their score change from the baseline were compared between the two treatment groups. Higher values indicate a worse outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.13","spread":"1.41"},{"groupId":"OG001","value":"-3.26","spread":"2.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.28","spread":"1.12"},{"groupId":"OG001","value":"-3.65","spread":"2.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.81","spread":"1.12"},{"groupId":"OG001","value":"-3.82","spread":"2.28"}]}]}]},{"type":"SECONDARY","title":"Sedation Scores and Time to Readiness for Discharge","description":"Time from study drug injection to time to readiness for discharge based on composite sedation score at readiness for discharge consist of Physician Sedation Score and Patient Sedation Score\n\nPhysician Sedation Score\n\nScore ranged from 0 to 4 (0=min, 4=max)\n\n0 = None (Patient is completely alert. Does not look tired at all), 1 = Mild (Patient sitting/lying comfortably, and looks tired), 2 = Moderate (Drowsy, with occasional eyes closing), 3 = Severe (Asleep, with eyes closed but responds to minor motor stimulation), 4 = Extremely Severe (Asleep; does not respond to minor motor stimulation)\n\nPatient Sedation Score\n\nScore ranged from 0 to 4 (0=min, 4=max)\n\n0 = None (Not drowsy at all), 1 = Mild (Slightly drowsy), 2 = Moderate (Quite drowsy), 3 = Severe (Extremely drowsy), 4 = Extremely Severe (Asleep, cannot self-rate)\n\nHigher the sedation score = worse outcome\n\nA composite sedation score which is the sum of the two parameters.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.19","spread":"0.40"},{"groupId":"OG001","value":"0.35","spread":"0.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"0.45"},{"groupId":"OG001","value":"0.71","spread":"0.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.44","spread":"0.81"},{"groupId":"OG001","value":"1.06","spread":"0.97"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Requiring Additional Medication","description":"Percentage of Patients Requiring Additional Medication (Rescue Medication)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Sedation Scores and Time to Readiness for Discharge HH:MM","description":"Time from study drug injection to time to readiness for discharge based on Physician and Patient Sedation Scores\n\nPhysician Sedation Score:\n\n0 = None\n\n1 = Mild 2 = Moderate 3= Severe 4 = Extremely Severe Patient Sedation Score 0= None\n\n1- Mild 2 = Moderate 3= Severe 4 = Extremely Severe Higher scores = worse outcome","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.65","spread":"0.53"},{"groupId":"OG001","value":"2.23","spread":"1.20"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":16},"commonTop":["Rash pruritic","Rash","Urticaria","Pruritis","Dizziness"]}}}